Anti-angiogenic therapy is a beneficial component in the treatment of multiple solid tumors given the importance of adequate blood supply for tumor growth and metastasis.3 Despite promising preclinical data and early clinical trials, anti-angiogenic agents have failed to show an overall survival benefit in randomized controlled trials of patients with glioblastoma.13,14,24,25 In particular, agents targeting VEGF appear to prolong PFS, possibly improve quality of life in some patients, and decrease steroid usage, yet the trials to date have demonstrated no improvement in overall survival. Here, VEGFA is linked to neoplasm.